Saturday, September 21, 2024
spot_img

Dual-drug therapy shows promise for treating alcohol use disorder

Date:

Share post:

spot_img
spot_img

New York, July 31 : A team of researchers has leveraged two new molecules, one of which is currently in clinical oncology trials, to devise a dual-drug therapy for alcohol use disorder (AUD), without the side-effects or complications associated with current treatment regimens.

The study, published in the journal Nature Communications, indicates that the approach had highly successful results in mice and may apply to other drugs that are often abused.

“Alcohol use disorder is really a process of maladapted learning and memory,” said researcher Dorit Ron from the University of California, San Francisco.

“Alcohol is rewarding, and we learn to associate alcohol, and even the environment in which we drink the alcohol, with that reward,” Ron added.

At the root of the team’s thinking is the idea that AUD and other substance abuse disorders are the results of reinforced pathways in the brain, and that those pathways can be blocked or redirected, ending cravings and habitual behaviour.

The researcher said she is studying the role of the enzyme mTORC1 in the creation of those memories and associations, to create an effective drug that can treat the neurological causes of AUD.

Ordinarily, mTORC1 is involved in brain plasticity, helping to create connections between neurons that reinforce memory. In previous work, Ron showed that consuming alcohol activates the enzyme in the brain.

Ron has also shown that blocking the activity of mTORC1 with the FDA-approved compound rapamycin, used to treat some types of cancer and suppress the immune response in transplant patients, can halt cravings in mice engineered for alcohol use disorder.

But mTORC1 contributes to a bevy of other bodily tasks related to metabolism and liver function, and people taking it for an extended period often develop liver toxicity, glucose intolerance, and other side effects.

Ron believes that tackling addiction from a neurological perspective has potential for broad applications.

“We could see these side effects in mice who are taking rapamycin or RapaLink-1, and then when you give Rapablock, it’s like magic, the side effects are gone,” Ron noted.(IANS)

spot_img
spot_img

Related articles

RG Kar case: Second Sandip Ghosh confidant reaches CBI office for interrogation

Kolkata, Sep 21: Another controversial and now-suspended doctor Avik Dey, known to be a close confidant of the...

Sri Lanka: Voting ends in Presidential election, first result expected before midnight

Colombo, Sep 21: The first postal vote result is likely to be out before midnight, Sri Lanka's Election...

Pakistan reports three more polio cases, bringing total to 21 in 2024

Islamabad, Sep 21: Pakistan reported three new cases of polio in the country's Balochistan, Sindh, and Khyber Pakhtunkhwa...

PM Modi arrives in Philadelphia, up next meeting with Biden and Quad Leaders’ Summit

Philadelphia, Sep 21: Prime Minister Narendra Modi arrived in Philadelphia, his first stop on the three-day visit of...